NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / India News / Cipla gets DCGI nod to import Moderna COVID-19 vaccine
    Next Article
    Cipla gets DCGI nod to import Moderna COVID-19 vaccine
    Moderna's mRNA COVID-19 vaccine will be the fourth shot to be available for use in India.

    Cipla gets DCGI nod to import Moderna COVID-19 vaccine

    By Siddhant Pandey
    Jun 29, 2021
    04:12 pm

    What's the story

    The Drugs Controller General of India (DCGI) has reportedly allowed the pharmaceutical firm Cipla to import the COVID-19 vaccine developed by US-based biotechnology company Moderna Inc.

    On Monday, the company had submitted an application seeking the DCGI's approval to import the vaccine.

    Moderna's mRNA vaccine will be the fourth shot to be available for use in India. It is over 90% effective.

    Quote

    'Permission granted for restricted use in emergency situations'

    An official source told PTI, "Drugs Controller General of India (DCGI) has granted permission to Cipla to import Moderna's COVID-19 vaccine for restricted emergency use in the country as per the provisions of the New Drugs and Clinical Trial Rules, 2019 under Drugs and Cosmetics Act, 1940."

    "This permission is for restricted use in emergency situations in public interest," the source said.

    Details

    7 days' safety data required before roll-out: Official

    The official said, "The firm has to submit seven days safety assessment of the vaccine in first 100 beneficiaries before rolling out of the vaccine for further immunization program, according to the approval order."

    Cipla is seeking clarity and guidance on factors such as pricing, quantity, and indemnity clause, sources informed CNBC TV-18.

    Reportedly, no commercial deal has been reached yet.

    US

    US to donate doses through COVAX: Moderna

    Additionally, the US government has notably agreed to donate some vaccine doses through the global COVAX initiative to India and has sought approval from the Central Drugs Standard Control Organisation (CDSCO), Moderna had said on Sunday.

    Cipla was previously close to committing over $1 billion as advance to the US firm for 50 million vaccine doses, according to PTI.

    Working mechanism

    How does Moderna's vaccine work?

    Moderna's two-dose vaccine is based on messenger RNA (mRNA) technology.

    The vaccine involves mRNA carrying the genetic information for SARS-CoV-2's spike protein, which it uses to invade host cells.

    After vaccination, this protein is translated into the viral spike protein, which triggers an immune response.

    The vaccine can be stored at -20°C for six months and 4°C for 30 days.

    Vaccines

    India already using Covishield, COVAXIN, Sputnik V

    India is already using the AstraZeneca-Oxford vaccine (labeled Covishield in India), Bharat Biotech's COVAXIN, and Russia's Sputnik V in its vaccination drive, which was launched on January 16, 2021.

    On June 1, India had waived testing of batches at the Central Drugs Laboratory for foreign-made vaccines that have already been approved by the US FDA, the United Kingdom's MHRA, or the World Health Organization.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    Vaccine
    CIPLA
    Moderna Inc

    Latest

    What is 'Ozempic teeth,' new side effect of weight-loss drug Health & Wellness
    Delhi Police busts ISI sleeper cell, arrests 2 agents  Delhi Police
    OpenAI outage: ChatGPT is down, mobile and web services affected OpenAI
    Jaishankar links Pahalgam attack to Pakistan Army chief's 'jihadist mindset' Jammu And Kashmir

    Vaccine

    China's COVID-19 vaccination rates climb as new outbreaks emerge Coronavirus
    Bharat Biotech to increase COVAXIN production by 200 million doses India
    Coronavirus: Only 3.8% vaccinated as death toll crosses 3 lakh Ministry of Health and Family Welfare
    India may not receive Pfizer, Moderna vaccine doses until 2023 Pfizer

    CIPLA

    Cipla boss calls Subhanu Saxena quits; cites family reasons India
    India's five most influential and successful women in finance India
    Cipla's new strawberry-flavored medicine can save kids from AIDS Africa
    India's five most influential and successful women in finance India

    Moderna Inc

    Moderna's COVID-19 vaccine gets FDA nod for phase 2 trial Oxford University
    Moderna's COVID-19 vaccine shows 'positive' results in human trials United States of America
    Why the vaccine for COVID-19 is still several months away Coronavirus
    Moderna's COVID-19 vaccine: When will it be available? COVID-19
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025